LEO Pharma, a leading global pharmaceutical company specialising in dermatology and critical care, has selected Veeva CRM to support its rapidly growing New Markets Europe region. LEO has started the deployment of Veeva CRM to its users in countries such as Hungary, Czech Republic, Slovakia, Poland, Romania, and Italy.
"We were looking for an innovative CRM solution that was aligned and harmonised across countries and could be deployed quickly. It became clear early on that Veeva had the most comprehensive and agile pharma CRM solution and offered the shortest timeframe to implementation," commented Rene J0rgensen, global manager CRM and e-tools for LEO Pharma A/S.
General Manager for LEO Hungary, Jozsef Vincze, added "Given our rapid growth and expansion into new markets and regions, we were searching for a flexible and easy to use system that would support our customer-focused and performance-driven strategies. Veeva CRM has everything we need."
Over the past four years, Veeva Systems has quickly become a leading global provider of Pharma CRM solutions. Because of its cloud-based platform, Veeva CRM requires no hardware or software to purchase, scale, or maintain. In addition, all Veeva customers benefit from free, automatic upgrades so users are always on the latest version of the software, aiding in regulatory compliance while enhancing overall system performance.
"We are delighted that LEO has selected Veeva as its partner for this critical commercial initiative. We believe our solutions and services will accelerate LEO's commercial effectiveness as their business continues to grow across the globe," said Dan Goldsmith, general manager for Veeva Europe.
"Implementing Veeva CRM will also ensure tailored interactions with our unique customers in these new markets. And with Veeva's launch of iRep we see a real opportunity to integrate our CRM and CLM solutions on the iPad to increase the efficiency, effectiveness, and connectivity of our field force in the future," concluded Rene Jorgensen.
Healthy lifestyle choices can offset genetic risk for brain diseases